Valuation: Tempus AI, Inc.

Market Cap 12.69B 11.34B 10.57B 9.61B 18.08B 1,229B 18.25B 127B 49.66B 625B 47.66B 46.62B 2,009B P/E 2026 *
-50.5x
P/E 2027 * -53.9x
Enterprise Value 13.29B 11.87B 11.07B 10.06B 18.93B 1,287B 19.11B 133B 52B 654B 49.91B 48.82B 2,104B EV / Sales 2026 *
8.33x
EV / Sales 2027 * 6.71x
Free-Float
61.4%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 2015-07-31
Director of Finance/CFO 40 2017-07-31
Chief Administrative Officer 55 2020-05-31
Director TitleAgeSince
Chairman 56 2015-07-31
Director/Board Member 53 2019-10-28
Director/Board Member 74 2017-08-31
Change 5-day change 1-year change 3-year change Capi.($)
-3.59%-12.00% - - 12.69B
-3.19%-3.19%+44.60%+87.98% 74.68B
-15.86%-16.16%+2.68%+51.09% 58.7B
-2.39%+0.50%+3.41%+31.33% 48.36B
-6.83%-9.34%+290.32%+632.82% 43.05B
-0.49%-1.59%+27.90%+28.58% 42.48B
-4.56%-2.93%-0.81%+101.55% 41.39B
-2.13%+1.07%+7.51%+50.31% 31.29B
-3.07%-4.34%-12.83%-15.25% 23.93B
-2.20%-8.26%-38.43%+306.45% 22.22B
Average -4.43%-2.63%+36.04%+141.65% 42.9B
Weighted average by Cap. -5.07%-1.88%+42.42%+134.07%

Financials

2026 *2027 *
Net sales 1.6B 1.42B 1.33B 1.21B 2.27B 155B 2.29B 15.96B 6.24B 78.51B 5.99B 5.86B 252B 1.97B 1.76B 1.64B 1.49B 2.8B 190B 2.83B 19.67B 7.69B 96.78B 7.38B 7.22B 311B
Net income -246M -220M -205M -186M -350M -23.82B -354M -2.46B -962M -12.1B -923M -903M -38.92B -236M -211M -197M -179M -337M -22.89B -340M -2.36B -924M -11.63B -887M -868M -37.4B
Net Debt 598M 534M 498M 453M 852M 57.93B 860M 5.98B 2.34B 29.44B 2.25B 2.2B 94.67B 496M 443M 413M 376M 707M 48.07B 714M 4.96B 1.94B 24.43B 1.86B 1.82B 78.55B
Projected Income Statement - Annual - Tempus AI, Inc.
Logo Tempus AI, Inc.
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
Employees
3,800
Date Price Change
26-10-08 €61.00 -3.59%
26-10-07 €63.27 -1.91%
26-10-06 €64.50 -13.79%
26-10-05 €74.82 +10.58%
26-10-02 €67.66 -1.50%
Trader
Investor
Global
Quality
ESG MSCI
A
Ratings Surperformance© - Tempus AI, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
70.35USD
Average target price
70.61USD
Spread / Average Target
+0.37%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Tempus AI, Inc.